Alkermes - About the company
Alkermes is a public company based in Dublin (Ireland), founded in 1987. It operates as a Developer of small molecule therapeutics and drug delivery technologies for multiple CNS diseases. Alkermes has raised $46M in funding. The company has 2867 active competitors, including 972 funded and 713 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Biogen and PTC Therapeutics.
Company Details
Developer of small molecule therapeutics and drug delivery technologies for multiple CNS diseases. The company is developing medicines for the treatment of central nervous system (CNS) diseases. The company has a diversified commercial product portfolio and a clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction, and multiple sclerosis.
- Website
- www.alkermes.com/
- Registered Address
- Waltham, Massachusetts
Key Metrics
Founded Year
1987
Location
Dublin, Ireland
Stage
Public
Total Funding
$46M in 6 rounds
Latest Funding Round
Investors
Ranked
89th among 2867 active competitors
Annual Revenue
$1B+ as on Dec 31, 2025
Employee Count
2,440 as on Aug 31, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Public
Legal entities associated with Alkermes
Alkermes is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
ALKERMES PLC. CIN: 1520262 , United States, Active | $1B+ (As on Dec 31, 2025) | - | - | |
Alkermes, Inc. CIN: 232472830 , United States, Active | Dec 26, 999 | - | 1662 (As on Dec 31, 2024) | - |
Alkermes's IPO details
Alkermes got listed on Jul 16, 1991.
Click here to take a look at Alkermes's IPO in detail
Sign up to download Alkermes' company profile
Alkermes's funding and investors
Alkermes has raised a total funding of $46M over 6 rounds. Its latest funding round was a Grant (prize money) round on Sep 30, 2010 for $*****. 1 investor participated in its latest round. Alkermes has 7 institutional investors.
Here is the list of recent funding rounds of Alkermes:
Filter this list
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Sep 30, 2010 | 9288095 | Grant (prize money) | 6789490 | 1361634 | 5609720 | 3504637 |
Feb 03, 2005 | 6203155 | Venture Debt | 7684187 | 8046267 | 9305439 | 2358793 |
Aug 19, 2003 | 4852942 | Post IPO | 4643252 | 4216856 | 8782850 | 4082349 |
View details of Alkermes's funding rounds and investors
Alkermes' founders and board of directors
Founder? Claim ProfileAlkermes' employee count trend
Alkermes has 2,440 employees as of Aug 26. Here is Alkermes's employee count trend over the years:
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Alkermes's Competitors and alternates
Top competitors of Alkermes include Jazz Pharmaceuticals, Biogen and PTC Therapeutics. Here is the list of Top 10 competitors of Alkermes, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd | Biogen 1978, Cambridge (United States), Public | Developer of therapies for neurodegenerative and immunology disorders | $80M | 78/100 | |
3rd | PTC Therapeutics 1998, South Plainfield (United States), Public | Developer of small molecule drugs for the treatment of rare diseases | $248M | 77/100 | |
4th | Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
5th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
10th | Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | 71/100 | |
89th | Developer of small molecule therapeutics and drug delivery technologies for multiple CNS diseases | $46M | 63/100 |
Looking for more details on Alkermes's competitors? Click here to see the top ones
Alkermes's Investments and acquisitions
Alkermes has made 3 investments in companies including Civitas Therapeutics and Civitas Therapeutics. Alkermes has also acquired 3 companies including Avadel Pharmaceuticals and Rodin Therapeutics.Here is the list of investments & acquisitions:
Filter this list
Date of Investment/Acquisition | Type | Company Name | Founded Year | Location |
|---|---|---|---|---|
Oct 22, 2025 | Acquisition | 1990 | Dublin (Ireland) | |
Nov 18, 2019 | Acquisition | 2013 | Cambridge (United States) | |
Aug 29, 2014 | Investments | 2009 | Chelsea (United States) |
See all acquisitions by Alkermes
Reports related to Alkermes
Here is the latest report on Alkermes's sector:
News related to Alkermes
Media has covered Alkermes for a total of 46 events in the last 1 year, 26 of them have been about company updates and 3 about people movement.
•
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1Business Wire•Aug 25, 2026•Alkermes, The Lancet
•
•
•
Alkermes Terminates VIVITROL Authorized Generic Supply Agreement With Amneal Without Penalties - AlkermesBenzinga•Jul 08, 2026•Alkermes, Amneal
•
Insider Selling: Alkermes (NASDAQ:ALKS) EVP Sells 9,000 Shares of Stocktickerreport.com•Jul 01, 2026•Alkermes
•
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026Business Wire•Jun 18, 2026•Alkermes
•
Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and EuropeBusiness Wire•Jun 15, 2026•Alkermes
•
•
•
Are you a Founder ?
FAQs about Alkermes
Explore our recently published companies
- Himsons - Vadodara based, 1988 founded, Unfunded company
- Com2uS Platform Corp - Unfunded company
- Just Print - Unfunded company